m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00172)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
AFF4
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | LX2 cell line | Homo sapiens |
Treatment: shMETTL3 LX2 cells
Control: shLuc LX2 cells
|
GSE207909 | |
Regulation |
|
logFC: -6.53E-01 p-value: 1.79E-17 |
More Results | Click to View More RNA-seq Results | |
Representative RIP-seq result supporting the interaction between AFF4 and the regulator | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Regulation | logFC: 1.64E+00 | GSE60213 |
In total 2 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | AF4/FMR2 family member 4 (AFF4), two key regulators of NF-Kappa-B pathway (IKBKB and RELA) and MYC were further identified as direct targets of METTL3-mediated m6A modification.overexpression of METTL3 significantly promoted Bladder cancer cell growth and invasion. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Bladder cancer | ICD-11: 2C94 | ||
Cell Process | Glucose metabolism | |||
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | METTL3 regulates the m6A modification and thereby the expression of AF4/FMR2 family member 4 (AFF4), knockdown of which phenocopies the METTL3 ablation and diminishes the tumor-initiating capability of bladder cancer stem cells in vivo. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Bladder cancer | ICD-11: 2C94 | ||
Pathway Response | Signaling pathways regulating pluripotency of stem cells | hsa04550 | ||
Cell Process | Self-renewal and tumorigenicity | |||
In-vitro Model | 5637 | Bladder carcinoma | Homo sapiens | CVCL_0126 |
UM-UC-3 | Bladder carcinoma | Homo sapiens | CVCL_1783 | |
Bladder cancer [ICD-11: 2C94]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | AF4/FMR2 family member 4 (AFF4), two key regulators of NF-Kappa-B pathway (IKBKB and RELA) and MYC were further identified as direct targets of METTL3-mediated m6A modification.overexpression of METTL3 significantly promoted Bladder cancer cell growth and invasion. | |||
Responsed Disease | Bladder cancer [ICD-11: 2C94] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Cell Process | Glucose metabolism | |||
Experiment 2 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | METTL3 regulates the m6A modification and thereby the expression of AF4/FMR2 family member 4 (AFF4), knockdown of which phenocopies the METTL3 ablation and diminishes the tumor-initiating capability of bladder cancer stem cells in vivo. | |||
Responsed Disease | Bladder cancer [ICD-11: 2C94] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Signaling pathways regulating pluripotency of stem cells | hsa04550 | ||
Cell Process | Self-renewal and tumorigenicity | |||
In-vitro Model | 5637 | Bladder carcinoma | Homo sapiens | CVCL_0126 |
UM-UC-3 | Bladder carcinoma | Homo sapiens | CVCL_1783 | |
References